NorthWest Biotherapeutics Inc (NWBO)

[Maverick0408]

No point arguing. These same folks were saying how the peer reviewed article and TLD were going to change the perception and potentially share price whenever those pieces were released. In fact, the opposite happened with the share price.

Before that, specials approval was hyped up as well and how that was going to change our revenue situation quickly in 2022. $20M per quarter estimates were forecasted for 2022. In fact, we are not even at $2M per quarter in mid 2023.

Nothing changes without a big pharma partner. In fact, I wouldn’t be surprised if our share price goes lower at MHRA approval if there is no partnership announcement to go along. Classic sell the news event that shorts will pounce on!